Sapienza University of Rome

RADIOPARP Phase 1 Trial Demonstrates Safety of Olaparib Combined with Radiotherapy in Triple-Negative Breast Cancer

- Long-term results from the RADIOPARP Phase 1 trial show that combining Olaparib with radiotherapy is safe for triple-negative breast cancer patients with residual disease. - The study demonstrates potential radiosensitizing effects of the PARP inhibitor Olaparib when used alongside breast radiation therapy. - The research approach is being extended to other cancer types, with the Gliofocus Phase 3 trial testing similar PARP inhibitor combinations in glioblastoma multiforme.